News
Overseas Business
StemCyte is a leading Regenerative Cell Therapy Company focused on developing cell therapy products as well as providing both public and private cell banking services in the USA and Taiwan.
Core Value
Cure
StemCyte offers both public and private cell banking services and consistently meets international quality accreditations such as AABB and FACT. We provide high-quality allogeneic cell materials to create the best solutions for cellular therapy.
Expansion
StemCyte is actively exploring the potential of cell therapy for emerging therapeutic applications. It includes Phase II clinical trials investigating the use of REGENECYTE in treating long-COVID and acute stroke, and Phase I clinical trials for cerebral palsy.
Lifesaving
StemCyte’s umbilical cord blood cell therapy, RegeneCyte, has successfully assisted over 2,300 cases of cord blood transplants worldwide. It receives U.S. FDA BLA approval on November 20th, 2024. StemCyte has become the first cell therapy company in the world to receive FDA approval for cord blood cell drugs.
Leadership
StemCyte, with its core focus on umbilical cord blood banking, is continuously developing cell therapy indications with the goal of sustainable business operations. It aspires to become a leading brand in the field of cell therapy and strives to make efforts in saving more lives.